Staphylococcus Aureus Toxic Shock Syndrome With Urinary Tract Infection
,
Abstract
Objective: To describe a rare case of non-menstrual staphylococcal toxic shock syndrome (TSS) with Staphylococcus aureus urinary tract infection as the suspected primary source and to highlight the successful use of linezolid as adjunctive therapy when clindamycin resistance is present.
Case report: A 42-year-old woman presented with fever, vomiting, diarrhea, and severe vulvar pain. One month prior, she experienced vaginal pruritus with excoriations and fissuring that never fully resolved. On examination, she had conjunctival injection, tongue inflammation with non-vesicular lesions, and a diffuse erythematous macular rash. Laboratory evaluation revealed elevated transaminases, thrombocytopenia, and bandemia. Urinalysis demonstrated 100,000 CFU of Staphylococcus aureus. Gynecologic examination revealed vulvar and vaginal erythema with ulcerated cervical lesions. Vaginal culture also grew heavy Staphylococcus aureus. Given the constellation of fever, rash, mucosal involvement, hepatic dysfunction, and positive Staphylococcus aureus cultures, a diagnosis of toxic shock syndrome was made. The isolate was resistant to clindamycin, necessitating treatment with vancomycin, piperacillin-tazobactam, and linezolid. The patient improved and completed 14 days of antibiotic therapy with complete resolution of symptoms.
Conclusion: Staphylococcus aureus urinary tract infection is an exceedingly rare source of toxic shock syndrome. Clinicians should maintain a high index of suspicion for TSS in patients with any staphylococcal infection presenting with fever and multisystem involvement. Linezolid is an effective alternative to clindamycin for toxin suppression, particularly in cases involving clindamycin-resistant organisms. Prior mucosal barrier disruption may be an important risk factor for TSS development.
2. Gottlieb M, Long B, Koyfman A. The Evaluation and Management of Toxic Shock Syndrome in the Emergency Department: A Review of the Literature. J Emerg Med. 2018;54(6):807-814.
3. Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009;9(5):281-90.
4. Contou D, Colin G, Travert B, Jochmans S, Conrad M, Lascarrou JB, et al. Menstrual toxic shock syndrome: a French nationwide multicenter retrospective study. Clin Infect Dis 2022; 74(2): 246–53.
5. Schlievert PM. Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet 1986; 1(8490): 1149-50.
6. Lee VT, Chang AH, Chow AW. Detection of staphylococcal enterotoxin B among toxic shock syndrome (TSS)- and non-TSS-associated Staphylococcus aureus isolates. J Infect Dis 1992; 166(4): 911–5.
7. Lehn N, Schaller E, Wagner H, Krönke M. Frequency of toxic shock syndrome toxin- and enterotoxin-producing clinical isolates of Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1995; 14(1): 43–6.
8. Schlievert PM. Role of superantigens in human disease. J Infect Dis 1993; 167(5): 997–1002.
9. Kum WW, Laupland KB, Chow AW. Defining a novel domain of staphylococcal toxic shock syndrome
toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality. Can J Microbiol 2000; 46(2): 171–9.
10. Bonventre PF, Linnemann C, Weckbach LS, Staneck JL, Buncher CR, Vigdorth E, et al. Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J Infect Dis 1984; 150(5): 662–6.
11. Bergdoll MS, Crass BA, Reiser RF, Robbins RN, Davis JP. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet 1981; 1(8228): 1017–21.
12. Centers for Disease Control (CDC). Reduced incidence of menstrual toxic-shock syndrome—United States, 1980–1990. MMWR Morb Mortal Wkly Rep 1990; 39(25): 421–3.
13. Gaventa S, Reingold AL, Hightower AW, Broome CV, Schwartz B, Hoppe C, et al. Active surveillance for toxic shock syndrome in the United States, 1986. Rev Infect Dis 1989; 11 Suppl 1: S28–34.
14. Sharma H, Smith D, Turner CE, Game L, Pichon B, Hope R, et al. Clinical and molecular epidemiology of staphylococcal toxic shock syndrome in the United Kingdom. Emerg Infect Dis 2018; 24(2): 258–66.
15. Descloux E, Perpoint T, Ferry T, Lina G, Bes M, Vandenesch F, et al. One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases. Eur J Clin Microbiol Infect Dis 2008; 27(1): 37–43.
16. McCahill PD, Whittle DI, Jacobs SC. Toxic shock syndrome: a complication of continent urinary diversion. J Urol 1992; 147(3): 681–2.
17. Pomputius WF, Kilgore SH, Schlievert PM. Probable enterotoxin-associated toxic shock syndrome caused
by Staphylococcus epidermidis. BMC Pediatr 2023; 23(1): 108.
18. Hutcherson TC, Cieri-Hutcherson NE, Grosshans MA, et al. Systematic review of intrauterine contraceptive use and the development of toxic shock syndrome. J Pharm Pract 2025; 38(5): 463–72.
19. Cho EE, Fernando D. Fatal streptococcal toxic shock syndrome from an intrauterine device. J Emerg Med 2013; 44(4): 777–80.
20. Balayla J, Gil Y, Mattina J, Al-Shehri E, Ziegler C. Streptococcal toxic shock syndrome after insertion of a levonorgestrel intrauterine device. J Obstet Gynaecol Can 2019; 41(12): 1772–4.
21. Cortés-Penfield N, Ryder JH. Should linezolid replace clindamycin as the adjunctive antimicrobial of choice in group A streptococcal necrotizing soft tissue infection and toxic shock syndrome? A focused debate. Clin Infect Dis 2023; 76(2): 346–50.
22. Babiker A, Warner S, Li X, Chishti EA, Saad E, Swihart BJ, et al. Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation. Lancet Infect Dis 2025; 25(3): 265–75.
| Files | ||
| Issue | Vol 20, No 1 (March 2026) | |
| Section | Case Reports | |
| Keywords | ||
| Shock Toxic Staphylococcus Aureus Urinary Tract Infections Vaginitis Linezolid Drug Resistance Bacterial Superantigens Anti-Bacterial Agents | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
